plerixafor has been researched along with Uterine Cervical Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chaudary, N; Han, K; Hill, RP; Lecavalier-Barsoum, M; Milosevic, M; Pintilie, M | 1 |
| Baleux, F; Brule, S; Charnaux, N; Friand, V; Gattegno, L; Sutton, A | 1 |
2 other study(ies) available for plerixafor and Uterine Cervical Neoplasms
| Article | Year |
|---|---|
Targeting CXCL12/CXCR4 and myeloid cells to improve the therapeutic ratio in patient-derived cervical cancer models treated with radio-chemotherapy.
Topics: Animals; Benzylamines; Chemokine CXCL12; Chemoradiotherapy; Cyclams; Female; Heterocyclic Compounds; Humans; Mice; Mice, Inbred C57BL; Myeloid Cells; Receptors, CXCR4; Signal Transduction; Uterine Cervical Neoplasms | 2019 |
Glycosaminoglycans and syndecan-4 are involved in SDF-1/CXCL12-mediated invasion of human epitheloid carcinoma HeLa cells.
Topics: Anthracenes; Benzylamines; Carcinoma in Situ; Cell Movement; Chemokine CXCL12; Cyclams; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Glycosaminoglycans; HeLa Cells; Heterocyclic Compounds; Humans; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Signal Transduction; Syndecan-4; Uterine Cervical Neoplasms | 2009 |